



## About Amgen

### Company History

Amgen Inc. was originally founded in 1980 as AMGen (Applied Molecular Genetics), with the company changing its name to Amgen in 1983. Amgen pioneered the development of novel and innovative products based on advances in recombinant DNA and molecular biology. More than a decade ago, Amgen introduced two of the first biologically derived human therapeutics, EPOGEN<sup>®</sup> (Epoetin alfa) and NEUPOGEN<sup>®</sup> (Filgrastim), which became the biotechnology industry's first blockbusters. These products have improved the lives of hundreds of thousands of patients suffering from conditions related to chronic kidney disease and cancer.

Today, Amgen is a Fortune 500 company whose business has expanded to serve patients around the world in supportive cancer care as well as the treatment of anemia, rheumatoid arthritis and other autoimmune diseases such as psoriatic arthritis. Amgen continues to sustain a culture based on biotechnology entrepreneurialism and innovation. As a science-based and patient-focused organisation, Amgen strives to follow the science wherever it may lead in order to best treat serious illness.

### Amgen in Australia

- Established in 1991.
- Corporate headquarters located in North Ryde, Sydney, New South Wales.
- Committed to improving quality of life in Australian communities.
- Currently markets the following products in Australia: Aranesp<sup>®</sup>, Kineret<sup>®</sup>, Kepivance<sup>™</sup>, Neulasta<sup>®</sup>, Neupogen<sup>®</sup>, Sensipar<sup>®</sup>, Stemgen<sup>™</sup> and Vectibix<sup>®</sup>.
- Supports a number of academic awards and scholarships to promote the advancement of scientific research in Australia.
- Approximately 10% of patients enrolled in Amgen global clinical trials are from Australia.

The Australian operations have become an integral part of Amgen's global development program.

### Quick Facts

#### Primary Locations

Head Office - Sydney

Research & Development – Melbourne

#### Other Australian offices

Brisbane  
Adelaide  
Perth

#### Full-Time Staff

156 (2007)

#### Contact details

Head Office (Sydney)  
Amgen Australia Pty Ltd  
Level 7, 123 Epping Road  
North Ryde NSW 2113  
Australia

T: +61 2 9870 1333

F: + 61 2 9870 1344

Email: [ausinfo@amgen.com](mailto:ausinfo@amgen.com)

Web: [www.amgen.com.au](http://www.amgen.com.au)

#### Key Contact

Medical Communications  
Phone: 1800 803 638 (toll free)

#### Principal Therapeutics

- Aranesp<sup>®</sup> (darbepoetin alfa)
- Kepivance<sup>™</sup> (palifermin)
- Kineret<sup>®</sup> (anakinra)
- Neulasta<sup>®</sup> (pegfilgrastim)
- NEUPOGEN<sup>®</sup> (Filgrastim)
- Sensipar<sup>®</sup> (cinacalcet HCl)
- STEMGEN<sup>™</sup> (Ancestim)
- Vectibix<sup>®</sup> (panitumumab)

## Research and Development (R&D)

Since 1980, Amgen has been a leading innovator in the identification, isolation, production and use of human proteins as therapeutic agents. Today, our scientists work at the cutting edge between the traditional disciplines of chemistry and cellular and molecular biology in an effort to discover and develop the medical breakthroughs of tomorrow.

Our focus is on pioneering treatments for serious illness and our R&D organisation has cultivated expertise in multiple treatment modalities – large-molecule proteins, small molecules and antibodies – allowing us to choose the best target for attacking disease and to use the modality most likely to affect that target.

## Commitment to Improve Australia's Healthcare System

As a global leader in developing and delivering breakthrough biologic medicines that improve the health and well-being for patients dealing with serious illnesses, Amgen is committed to working with Australia's Federal government and other stakeholders to develop practical, cost-effective and long-term ways to sustain and improve Australia's health care system.

Biologic medicines have the ability to change the practice of medicine like never before, helping millions of people in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. We welcome the opportunity to work together with patients, doctors, industry, healthcare practitioners and government to find healthcare solutions that are in the best interests of all Australians.

## Amgen in the Australian Community

Amgen Australia is committed to improving quality of life, not only for patients who benefit from Amgen therapeutics, but also for people in Australian communities.

Amgen Australia provides charity and community support to organisations at both a national and local level. Staff members are encouraged to involve themselves in charity activities, and Amgen provides special leave days to allow staff to volunteer their time to the community. Under this program, many Amgen staff have volunteered their time to worthy causes such as The Australian Transplant Games and Aboriginal Health Weekends to promote kidney disease awareness and prevention.

### Did you know?

While Amgen established offices in Australia in 1991, clinical research in the region actually started much earlier.

In 1987, Phase I clinical trial work for Neupogen<sup>®</sup> was carried out in Melbourne. Since then, Amgen Australia has been involved in 180, (162 Clinical Development, 18 Medical Affairs) trials.

Today, approximately 10% of patients enrolled in Amgen global clinical trials are from Australia.

### The Amgen Difference - Our Values

At Amgen, we hold our values in high regard and they are the foundation upon which we work.

Our values form a deeply held belief system that guides our behaviour, help us make decisions and build the framework for our daily interactions with each other.

#### Results

- Be science-based
- Work in teams
- Compete intensely and win
- Create value for patients, staff and stockholders

#### People

- Trust and respect each other
- Collaborate, communicate and be accountable

#### Integrity

- Ensure quality
- Be ethical